Compare Novo Nordisk A/S (NVO) vs Vipshop Holdings Ltd - ADR (VIPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Vipshop Holdings Ltd - ADR — how do they compare? Novo Nordisk A/S trades at $46.24 (market cap $207.85B), while Vipshop Holdings Ltd - ADR trades at $14.34 (market cap $7.20B). The key difference: Novo Nordisk A/S is far larger — about 28.9× Vipshop Holdings Ltd - ADR's market cap, and Vipshop Holdings Ltd - ADR pays the higher dividend (4.14%). Which is the better fit depends on your goals.
| NVO | VIPS | |
|---|---|---|
Market Cap | $207.85B | $7.20B |
Sector | Health | Consumer Cyclical |
52-Week High | $63.98 | $20.68 |
52-Week Low | $35.29 | $12.92 |
Enterprise Value | $222.55B | $3.76B |
Dividend Yield | 3.81% | 4.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Vipshop (VIPS) trades at $15.41, down 1.72% on the day, with a bullish technical signal from moving averages. The stock shows attractive valuation metrics, including a P/E of 6.79 and P/S of 0.48, while maintaining solid profitability with a net income margin of 7.07%. Recent Q1 2026 earnings met expectations, and the company is pursuing growth through an outlet store REIT strategy, as reported by Seeking Alpha on May 22, 2026.
The outlook is cautiously positive, supported by low valuations and analyst consensus, but risks include revenue stagnation and macroeconomic pressures in China. Near-term catalysts depend on Q2 2026 earnings beating the $0.62 EPS estimate to reaffirm growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →
